# US 2025/0026843 A1 · Bispecific antibody against cd40 and cldn18.2 and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0026843 A1
- Document ID: US20250026843A1
- Status: Published application
- Kind: A1
- Application number: 18/715,119
- Filed: 2022-12-28
- Published: 2025-01-23
- Earliest claimed: 2021-12-30
- Assignees: Anhui Biox-Vision Biological Technology Co., Ltd.
- Applicants: Anhui Biox-Vision Biological Technology Co., Ltd.
- Inventors: Guojun LANG; Wenhai ZHANG; Guoxing WANG; Run YAN; Zhen ZHANG; Yuhao HU; Peipei LIU; Li FAN; Yongcong TAN
- Web page: https://patentgrep.com/patent/US20250026843A1

## CPC

- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61P 35/00: Antineoplastic agents
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61K 2039/505: {comprising antibodies}
- C07K 2317/31: multispecific
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A bispecific antibody targeting both CD40 and CLDN18.2, a pharmaceutical composition comprising same, an application thereof for treating related diseases, and a treatment method are provided. The bispecific antibody targeting both CD40 and CLDN18.2 comprises (i) an anti-CD40 antibody or a fragment thereof and (ii) an anti-CLDN18.2 antibody or a fragment thereof.

## Claims

### Claim 1

An anti-CD40×CLDN18.2 bispecific antibody, comprising (i) an anti-CD40 antibody or a fragment thereof and (ii) an anti-CLDN18.2 antibody or a fragment thereof, wherein:
the anti-CD40 antibody or the fragment thereof comprises 3 heavy chain CDRs contained in SEQ ID NO:11 or variants thereof and comprises 3 light chain CDRs contained in SEQ ID NO:10 or variants thereof;
the anti-CD40 antibody or the fragment thereof comprises 3 heavy chain CDRs contained in SEQ ID NO: 12 or variants thereof and comprises 3 light chain CDRs contained in SEQ ID NO:10 or variants thereof;
the anti-CD40 antibody or the fragment thereof comprises 3 heavy chain CDRs contained in SEQ ID NO:13 or variants thereof and comprises 3 light chain CDRs contained in SEQ ID NO: 10 or variants thereof; or
the anti-CD40 antibody or the fragment thereof comprises 3 heavy chain CDRs contained in SEQ ID NO: 14 or variants thereof and comprises 3 light chain CDRs contained in SEQ ID NO: 10 or variants thereof, wherein
the variants have one or two amino acid substitutions, additions, and/or deletions compared to sequences derived therefrom.

### Claim 2 (depends on 1)

The bispecific antibody according to claim 1, wherein the anti-CLDN18.2 antibody or the fragment thereof is a single domain antibody (VHH), and the single domain antibody comprises 3 CDRs contained in SEQ ID NO:18 or variants thereof, wherein
the variants have one or two amino acid substitutions, additions, and/or deletions compared to sequences derived therefrom.

### Claim 3 (depends on 1)

The bispecific antibody according to claim 1, comprising:
(i) a heavy chain with a structure VH-CH1-Fc-VHH, and
(ii) a light chain with a structure VL-CL, wherein
the VH comprises 3 heavy chain CDRs contained in SEQ ID NO:11, the VL comprises 3 light chain CDRs contained in SEQ ID NO:10, and the VHH comprises 3 CDRs contained in SEQ ID NO:18;
the VH comprises 3 heavy chain CDRs contained in SEQ ID NO: 12, the VL comprises 3 light chain CDRs contained in SEQ ID NO:10, and the VHH comprises 3 CDRs contained in SEQ ID NO:18;
the VH comprises 3 heavy chain CDRs contained in SEQ ID NO:13, the VL comprises 3 light chain CDRs contained in SEQ ID NO:10, and the VHH comprises 3 CDRs contained in SEQ ID NO:18; or
the VH comprises 3 heavy chain CDRs contained in SEQ ID NO:14, the VL comprises 3 light chain CDRs contained in SEQ ID NO:10, and the VHH comprises 3 CDRs contained in SEQ ID NO: 18.

### Claim 4 (depends on 1)

The bispecific antibody according to claim 1, comprising:
(i) a heavy chain with a structure VH-CH1-Fc-VHH, and
(ii) a light chain with a structure VL-CL, wherein
the VH comprises 3 heavy chain CDRs shown in SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, the VL comprises 3 light chain CDRs shown in SEQ ID NO:1, SEQ ID NO: 2, and SEQ ID NO:3, and the VHH comprises 3 CDRs shown in SEQ ID NO: 15, SEQ ID NO:16, and SEQ ID NO:17;
the VH comprises 3 heavy chain CDRs shown in SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:7, the VL comprises 3 light chain CDRs shown in SEQ ID NO:1, SEQ ID NO: 2, and SEQ ID NO:3, and the VHH comprises 3 CDRs shown in SEQ ID NO: 15, SEQ ID NO:16, and SEQ ID NO:17;
the VH comprises 3 heavy chain CDRs shown in SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:8, the VL comprises 3 light chain CDRs shown in SEQ ID NO:1, SEQ ID NO: 2, and SEQ ID NO:3, and the VHH comprises 3 CDRs shown in SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17; or
the VH comprises 3 heavy chain CDRs shown in SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:9, the VL comprises 3 light chain CDRs shown in SEQ ID NO:1, SEQ ID NO: 2, and SEQ ID NO:3, and the VHH comprises 3 CDRs shown in SEQ ID NO:15, SEQ ID NO: 16, and SEQ ID NO: 17.

### Claim 5 (depends on 1)

The bispecific antibody according to claim 1, wherein:
the VH comprises a sequence shown in SEQ ID NO:11 or a sequence having at least 90% identity with SEQ ID NO:11, the VL comprises a sequence shown in SEQ ID NO: 10 or a sequence having at least 90% sequence identity with SEQ ID NO:10, and the VHH comprises a sequence shown in SEQ ID NO: 18 or a sequence having at least 90% sequence identity with SEQ ID NO:18;
the VH comprises a sequence shown in SEQ ID NO: 12 or a sequence having at least 90% identity with SEQ ID NO: 12, the VL comprises a sequence shown in SEQ ID NO: 10 or a sequence having at least 90% sequence identity with SEQ ID NO:10, and the VHH comprises a sequence shown in SEQ ID NO:18 or a sequence having at least 90% sequence identity with SEQ ID NO:18;
the VH comprises a sequence shown in SEQ ID NO:13 or a sequence having at least 90% identity with SEQ ID NO:13, the VL comprises a sequence shown in SEQ ID NO: 10 or a sequence having at least 90% identity with SEQ ID NO: 10, and the VHH comprises a sequence shown in SEQ ID NO:18 or a sequence having at least 90% identity with SEQ ID NO:18; or
the VH comprises a sequence shown in SEQ ID NO: 14 or a sequence having at least 90% identity with SEQ ID NO:14, the VL comprises a sequence shown in SEQ ID NO: 10 or a sequence having at least 90% sequence identity with SEQ ID NO: 10, and the VHH comprises a sequence shown in SEQ ID NO: 18 or a sequence having at least 90% sequence identity with SEQ ID NO:18.

### Claim 6 (depends on 1)

The bispecific antibody according to claim 1, wherein the VHH is connected to Fc through a linker, preferably, the linker is (G4S) n, where n is an integer equal to or greater than 1, for example, n is an integer of 1, 2, 3, 4, 5, 6, 7, 8, or 9, more preferably, the linker is selected from (G4S)3.

### Claim 7 (depends on 1)

The bispecific antibody according to claim 1, wherein an Fc region is an Fc region of an IgG class antibody, such as an Fc region of IgG1, such as an Fc region of a modified IgG1, such as an Fc region of IgG1 with an N297Q mutation.

### Claim 8 (depends on 1)

The bispecific antibody according to claim 1, wherein a light chain constant domain CL of the antibody is from κ or λ.

### Claim 9 (depends on 1)

The bispecific antibody according to claim 1, comprising:
(i) a heavy chain with a structure VH-CH1-Fc-VHH, and
(ii) a light chain with a structure VL-CL, wherein
the heavy chain comprises a sequence shown in SEQ ID NO: 19 or a sequence at least 90% identical to SEQ ID NO:19, and the light chain comprises a sequence shown in SEQ ID NO:23 or a sequence at least 90% identical to SEQ ID NO:23;
the heavy chain comprises a sequence shown in SEQ ID NO:20 or a sequence at least 90% identical to SEQ ID NO:20, and the light chain comprises a sequence shown in SEQ ID NO:23 or a sequence at least 90% identical to SEQ ID NO:23;
the heavy chain comprises a sequence shown in SEQ ID NO:21 or a sequence at least 90% identical to SEQ ID NO:21, and the light chain comprises a sequence shown in SEQ ID NO:23 or a sequence at least 90% identical to SEQ ID NO:23; or
the heavy chain comprises a sequence shown in SEQ ID NO:22 or a sequence at least 90% identical to SEQ ID NO:22, and the light chain comprises a sequence shown in SEQ ID NO:23 or a sequence at least 90% identical to SEQ ID NO:23.

### Claim 10 (depends on 1)

A polynucleotide encoding the bispecific antibody according to claim 1.

### Claim 11 (depends on 10)

A vector comprising the polynucleotide according to claim 10, preferably being an expression vector.

### Claim 12 (depends on 10)

A host cell comprising the polynucleotide according to claim 10.

### Claim 13 (depends on 1)

A method for producing the bispecific antibody according to claim 1, comprising steps of (i) culturing the host cell of the present invention under conditions suitable for expressing the bispecific antibody of the present invention, and optionally, (ii) recovering the bispecific antibody of the present invention.

### Claim 14 (depends on 1)

An immunoconjugate, a kit, a pharmaceutical composition, a combination product, or a preparation comprising the bispecific antibody according to claim 1.

### Claim 15 (depends on 14)

The kit, the pharmaceutical composition, the combination product, or the preparation according to claim 14, further comprising other therapeutic agents and optional pharmaceutical aids, wherein preferably, the other therapeutic agents are selected from chemotherapeutic agents and cytotoxic agents.

### Claim 16 (depends on 1)

A use of the bispecific antibody according to claim 1 in a medicament or a kit for treating, preventing, and/or diagnosing a disease related to CD40 or a disease related to CLDN18.2, wherein preferably, the disease related to CLDN18.2 is a cancer in which CLDN18.2 is aberrantly expressed, and the disease related to CD40 is a cancer in which CD40 is aberrantly expressed.

### Claim 17 (depends on 1)

A method for treating a disease related to CD40 or a disease related to CLDN18.2, comprising administering a therapeutically effective amount of the bispecific antibody according to claim 1 to a patient in need.
